Logo image of PRPH

PROPHASE LABS INC (PRPH) Stock Fundamental Analysis

NASDAQ:PRPH - Nasdaq - US74345W1080 - Common Stock - Currency: USD

0.2633  -0.16 (-38.02%)

After market: 0.3382 +0.07 (+28.45%)

Fundamental Rating

3

Taking everything into account, PRPH scores 3 out of 10 in our fundamental rating. PRPH was compared to 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of PRPH have multiple concerns. PRPH has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PRPH had negative earnings in the past year.
In the past year PRPH has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: PRPH reported negative net income in multiple years.
PRPH had negative operating cash flow in 4 of the past 5 years.
PRPH Yearly Net Income VS EBIT VS OCF VS FCFPRPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

1.2 Ratios

PRPH has a Return On Assets of -30.23%. This is comparable to the rest of the industry: PRPH outperforms 54.30% of its industry peers.
The Return On Equity of PRPH (-72.80%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -30.23%
ROE -72.8%
ROIC N/A
ROA(3y)3.3%
ROA(5y)-4.41%
ROE(3y)1.95%
ROE(5y)-8.33%
ROIC(3y)N/A
ROIC(5y)N/A
PRPH Yearly ROA, ROE, ROICPRPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRPH Yearly Profit, Operating, Gross MarginsPRPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 300 400

More info and screens

2

2. Health

2.1 Basic Checks

PRPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRPH has been increased compared to 1 year ago.
The number of shares outstanding for PRPH has been increased compared to 5 years ago.
Compared to 1 year ago, PRPH has a worse debt to assets ratio.
PRPH Yearly Shares OutstandingPRPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
PRPH Yearly Total Debt VS Total AssetsPRPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -1.21, we must say that PRPH is in the distress zone and has some risk of bankruptcy.
PRPH's Altman-Z score of -1.21 is in line compared to the rest of the industry. PRPH outperforms 47.31% of its industry peers.
PRPH has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
PRPH has a Debt to Equity ratio (0.29) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Altman-Z -1.21
ROIC/WACCN/A
WACC13.39%
PRPH Yearly LT Debt VS Equity VS FCFPRPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.47 indicates that PRPH should not have too much problems paying its short term obligations.
With a Current ratio value of 1.47, PRPH is not doing good in the industry: 74.73% of the companies in the same industry are doing better.
PRPH has a Quick Ratio of 1.33. This is a normal value and indicates that PRPH is financially healthy and should not expect problems in meeting its short term obligations.
PRPH's Quick ratio of 1.33 is on the low side compared to the rest of the industry. PRPH is outperformed by 72.04% of its industry peers.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.33
PRPH Yearly Current Assets VS Current LiabilitesPRPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for PRPH have decreased strongly by -113.56% in the last year.
Looking at the last year, PRPH shows a very negative growth in Revenue. The Revenue has decreased by -79.66% in the last year.
The Revenue has been growing by 27.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-113.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)-79.66%
Revenue growth 3Y45.2%
Revenue growth 5Y27.64%
Sales Q2Q%-62.39%

3.2 Future

The Earnings Per Share is expected to grow by 58.10% on average over the next years. This is a very strong growth
PRPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 63.73% yearly.
EPS Next Y36.51%
EPS Next 2Y58.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.53%
Revenue Next 2Y63.73%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PRPH Yearly Revenue VS EstimatesPRPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
PRPH Yearly EPS VS EstimatesPRPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 0.5 -0.5 1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

PRPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 0.54 indicates a rather cheap valuation of PRPH.
Based on the Price/Forward Earnings ratio, PRPH is valued cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 92.56. PRPH is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 0.54
PRPH Price Earnings VS Forward Price EarningsPRPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRPH Per share dataPRPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PRPH's earnings are expected to grow with 58.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.1%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PRPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROPHASE LABS INC

NASDAQ:PRPH (1/31/2025, 8:00:00 PM)

After market: 0.3382 +0.07 (+28.45%)

0.2633

-0.16 (-38.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners9.58%
Inst Owner Change11.8%
Ins Owners17.47%
Ins Owner Change0%
Market Cap6.28M
Analysts82.86
Price Target18.87 (7066.73%)
Short Float %0.48%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-494.95%
Min EPS beat(2)-957.84%
Max EPS beat(2)-32.05%
EPS beat(4)1
Avg EPS beat(4)-251.68%
Min EPS beat(4)-957.84%
Max EPS beat(4)75.49%
EPS beat(8)2
Avg EPS beat(8)-192.35%
EPS beat(12)5
Avg EPS beat(12)-110.27%
EPS beat(16)6
Avg EPS beat(16)-181.27%
Revenue beat(2)0
Avg Revenue beat(2)-82.68%
Min Revenue beat(2)-87.07%
Max Revenue beat(2)-78.3%
Revenue beat(4)0
Avg Revenue beat(4)-72.33%
Min Revenue beat(4)-87.07%
Max Revenue beat(4)-60.09%
Revenue beat(8)2
Avg Revenue beat(8)-38.18%
Revenue beat(12)6
Avg Revenue beat(12)-8.82%
Revenue beat(16)9
Avg Revenue beat(16)-7.03%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)169.23%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)57.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.54
P/S 0.49
P/FCF N/A
P/OCF N/A
P/B 0.16
P/tB 0.28
EV/EBITDA N/A
EPS(TTM)-1.26
EYN/A
EPS(NY)0.49
Fwd EY185.95%
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0.53
BVpS1.6
TBVpS0.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.23%
ROE -72.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)3.3%
ROA(5y)-4.41%
ROE(3y)1.95%
ROE(5y)-8.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.48%
Cap/Sales 19.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.33
Altman-Z -1.21
F-Score1
WACC13.39%
ROIC/WACCN/A
Cap/Depr(3y)88.09%
Cap/Depr(5y)139.47%
Cap/Sales(3y)5.22%
Cap/Sales(5y)5.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-113.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y36.51%
EPS Next 2Y58.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-79.66%
Revenue growth 3Y45.2%
Revenue growth 5Y27.64%
Sales Q2Q%-62.39%
Revenue Next Year15.53%
Revenue Next 2Y63.73%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-130.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year185.63%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-179.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-161.39%
OCF growth 3YN/A
OCF growth 5YN/A